SCHEMBL3736701

SCHEMBL3736701

C[C](C)C(=O)N1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
CA2 P00918 1/20 0.42
CHKA P35790 1/20 0.42
ATM Q13315 1/20 0.40
HPGD P15428 2/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
LIPE Q05469 1/20 0.36
P2RX1 P51575 1/20 0.36
P2RX3 P56373 1/20 0.36
P2RX4 Q99571 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039385 0.82 ALDH1A1 (0.46) ALDH1A1CA2CHKAATMHPGD
SCHEMBL8288869 0.81 ALDH1A1 (0.56) ALDH1A1CA2CHKAATMHPGD
SCHEMBL11284764 0.80 ALDH1A1 (0.50) ALDH1A1CA2CHKAATMHPGD
SCHEMBL3999543 0.80 ALDH1A1 (0.50) ALDH1A1CA2CHKAATMHPGD
SCHEMBL109476 0.78 ALDH1A1 (0.42) ALDH1A1CA2CHKAATMHPGD
SCHEMBL4840666 0.78 ALDH1A1 (0.61) ALDH1A1CA2CHKAATMHPGD
SCHEMBL4261207 0.78 ALDH1A1 (0.61) ALDH1A1CA2CHKAATMHPGD
SCHEMBL9717393 0.78 ALDH1A1 (0.61) ALDH1A1CA2CHKAATMHPGD
SCHEMBL8024247 0.78 ALDH1A1 (0.61) ALDH1A1CA2CHKAATMHPGD
SCHEMBL11889662 0.78 ALDH1A1 (0.58) ALDH1A1CA2CHKAATMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US claimed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP claimed
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ASTRAZENECA AB (SE) 2008-07-31 US claimed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO claimed
US-11851449-B2 Heterocyclic amide compounds having an RORvt inhibitory action TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-26 US disclosed
EP-3018123-B1 AMIDE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-05-10 EP disclosed
US-20210277030-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-09 US disclosed
US-11053262-B2 Heterocyclic amide compounds having RORyT inhibitory action TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-07-06 US disclosed
US-10472376-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-12 US disclosed
US-20170107240-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-20 US disclosed
EP-3018123-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-05-11 EP disclosed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP disclosed
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ASTRAZENECA AB (SE) 2008-07-31 US disclosed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R ALDH1A1 1976/4885CA2 41/4885CHKA 236/4885
US-20170107240-A1 AMIDE COMPOUND RORB, RORC, RORA ALDH1A1 380/4885CA2 633/4885CHKA 3054/4885
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ITGB1, ITGA2B, ITGB5 ALDH1A1 345/4885CA2 2776/4885CHKA 1338/4885
US-20210277030-A1 AMIDE COMPOUND RORB, RORC, RORA ALDH1A1 380/4885CA2 633/4885CHKA 3054/4885
US-11851449-B2 Heterocyclic amide compounds having an RORvt inhibitory action RORB, RORC, RORA ALDH1A1 232/4885CA2 385/4885CHKA 2968/4885
US-11053262-B2 Heterocyclic amide compounds having RORyT inhibitory action RORC, RORB, RORA ALDH1A1 336/4885CA2 378/4885CHKA 1928/4885
US-10472376-B2 Amide compound RORB, RORC, RORA ALDH1A1 380/4885CA2 633/4885CHKA 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.